Monotherapy with hypomethylating agents (HMA) remains the standard of care for patients with higher-risk myelodysplastic neoplasms (HR-MDS). Recently, the randomized phase III VERONA study evaluating azacitidine
Pre-mRNA splicing gene mutations are common in MDS and CMML and induce R-loops which trigger ATR activation. We studied ceralasertib, an orally bioavailable ATR inhibitor, in adult patients with R/R MDS or CMML in a phase Ib/II study including a safety run-in and expansion of 160mg BID during a 28-day cycle on two schedules: days 1-14 (14on/14off) or days 1-7 and 15- 21 (7on/7off). Response rates and survival were estimated. Forty-four evaluable patients were treated.
Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML), Leukemia, Myelodysplastic Syndromes (MDS), Myelofibrosis, Myeloproliferative Neoplasms (MPNs) Dr. Chan received her MD degree from the University of Arizona College of Medicine, Phoenix. She completed an Internal Medicine Residency at the University of Arizona College of Medicine in Tucson, followed by a Hematology/Oncology Fellowship at Moffitt Cancer Center/University of South Florida. Dr. Chan’s clinical interests include myeloid malignancies, specifically myelodysplastic syndrome (MDS) and
“I would like other families to know that they are incredibly inspiring and strong. You are the foundations for patients with MDS to fight, you are their strength, their heart and their cheerleaders. Even when you're hurting, you show up for them, and you deserve to be recognized for the love you have for your family member that is fighting MDS. Never forget how important you are in this process.”
TP53-mutated (TP53-mt) myelodysplastic syndromes (MDS) are aggressive myeloid neoplasms associated with inferior responses to conventional chemotherapy and a high risk of progression to acute myeloid leukemia (AML).1-3 Although multiple targeted and immunotherapeutic strategies…